NeuroAge Therapeutics, Inc.

The NeuroAge Test predicts how fast your brain is aging using AI, brain MRI, cognitive testing, blood biomarkers, and genetics. We offer personalized recommendations to slow down brain aging.

We have a beta version of the test currently available for clients in 13 states in >50 MRI clinics and three countries. We have started creating partnerships with longevity clinics, private wellness clubs, and large consumer facing MRI centers. We have established partnerships with 9 longevity clinics and have just last week started being offered to their clients. We are launching the consumer facing NeuroAge Test on December 5th- https://www.globenewswire.com/news-release/2024/11/26/2987168/0/en/NeuroAge-Therapeutics-Revolutionary-Brain-Health-Test-Predicts-Dementia-Risk-30-Years-in-Advance.h

More than 55M people worldwide have Alzheimer's disease. The biggest risk factor for Alzheimer's is brain aging, which is 40% due to lifestyle. We don't currently have a way to track brain aging for future risk of Alzheimer's in the way that we track risk factors for other diseases, like tracking cholesterol for future risk of heart disease.

We have created a test for brain aging that can predict Alzheimer's risk more than 30 years ahead of time. It has 4 parts: brain MRI, cognitive testing, proprietary blood biomarkers, and genetics. We combine these results into a single score for brain age using AI. We then offer our clients personalized lifestyle and health recommendations to lower their brain age, improve their cognitive health, and prevent future neurodegenerative diseases. The data we collect from these results helps us and others create personalized therapeutics for neurodegenerative diseases.

We started going to market through private clinics and longevity clinics to out of pocket payers. We are now launching the consumer facing test. We are a yearly subscription service. Our long-term vision is for the test be only a blood test given at yearly wellness exams like cholesterol testing. We are running a clinical study funded by ADDF/Gates Ventures to gather data for FDA approval.

Berkeley SkyDeck, the Batchery, the National Institute on Aging Startup Challenge